CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...
Ellipses Pharma ("Ellipses"), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for ...
2d
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung ...
The highly selective RET inhibitor pralsetinib (Gavreto) achieved "rapid, robust, and durable" anti-tumor activity in patients with a variety of RET fusion-positive solid tumors, an analysis of the ...
RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...
Findings demonstrated that Gavreto could clinically benefit those with RET fusion-positive non-small cell lung cancer, including those who are treatment naïve. Patients with RET fusion positive ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions, regardless of tumor type. The highly selective RET inhibitor pralsetinib was ...
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer ...
The approvals were based on data from the LIBRETTO-001 trial. The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo ® (selpercatinib) for adults with locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results